Evidence map›Paper›PMID 28831024›Full record

ArticleBioscience reports2017

Effect of Liuweibuqi capsules on the balance between MMP-9 and TIMP1 and viability of alveolar macrophages in COPD.

Chengyang Wang, Huanzhang Ding, Xiao Tang, Zegeng Li, Lei Gan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioscience reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chengyang WangDepartment of Traditional Chinese Medicine, The First Affiliated Hospital, Anhui Medical University, Hefei 230022, China.
Huanzhang DingGraduate School, Anhui University of Chinese Medicine, Hefei 230022, China.
Xiao TangGraduate School, Anhui University of Chinese Medicine, Hefei 230022, China.
Zegeng LiAnhui Academy of Chinese Medicine, Hefei 230022, China zegeng_li@sohu.com.
Lei GanDepartment of Traditional Chinese Medicine, The First Affiliated Hospital, Anhui Medical University, Hefei 230022, China.
Anhui University of Traditional Chinese Medicine · CNShandong Academy of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aims to investigate the effect of Liuweibuqi (LWBQ) capsules on the expression of matrix metalloproteinase (MMP)-9 and TIMP1 and cell viability of alveolar macrophages (AMs) in chronic obstructive pulmonary disease (COPD). Rats were randomly divided into normal control (NC) group, model control (MC) group, Jinshuibao (JSB) group, spleen aminopeptidase (PAT) group, and low dose of LWBQ (LWBQ low), mid dose of LWBQ (LWBQ mid), and high dose of LWBQ (LWBQ high) group (

Indexed as

AnimalsAnti-Inflammatory AgentsCell SurvivalCytokinesDrugs, Chinese HerbalMacrophages, AlveolarMaleMatrix Metalloproteinase 9Pulmonary Disease, Chronic ObstructiveRats, Sprague-DawleyTissue Inhibitor of Metalloproteinase-1Anti-Inflammatory AgentsCytokinesDrugs, Chinese HerbalMatrix Metalloproteinase 9TIMP1 protein, ratTissue Inhibitor of Metalloproteinase-1chronic obstructive pulmonary diseaseinflammatory cytokinesLiuweibuqi capsulesMMP-9TIMP1

Identifiers

PMID28831024
PMCPMC5603752
OpenAlexW2748545976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.